PCSK9 and acute coronary syndrome: PCSK9 inhibitors have been reported to have a rapid effect, a vast range of lipid reduction, a long duration of action, and an anti-inflammatory effect, providing a new dawn for further reducing MACEs of acute coronary syndrome (ACS) patients who underwent PCI [12–14].